Skip to search formSkip to main contentSkip to account menu

LASSBio 294

Known as: (2'-thienylidene)-3,4-methylenedioxybenzoylhydrazine, LASSBio-294, LASSBio294 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

HydrazonesThiophenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Etude de la cristallisation d’une nouvelle molécule à efficacité cardiotonique dans un mélange liquide ionique - eau
La cristallisation par effet anti-solvant, comme technique de production de micro/nanoparticules, presente certains inconvenients… 
2013
2013
Impairment of locomotor activity induced by the novel N-acylhydrazone derivatives LASSBio-785 and LASSBio-786 in mice
The N-acylhydrazone (NAH) analogues N-methyl 2-thienylidene 3,4-benzoylhydrazine (LASSBio-785) and N-benzyl 2-thienylidene 3,4… 
2012
2012
Combination of docking, molecular dynamics and quantum mechanical calculations for metabolism prediction of 3,4-methylenedioxybenzoyl-2-thienylhydrazone
AbstractIn modern drug discovery process, ADME/Tox properties should be determined as early as possible in the test cascade to… 
2010
2010
Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.
2010
2010
Structure-based prediction and biosynthesis of the major mammalian metabolite of the cardioactive prototype LASSBio-294.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)